Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab emtansine - Immunogen/Roche

Next Previous
X
Search
Drug Profile

Trastuzumab emtansine - Immunogen/Roche

Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Herceptin-DM1; Kadcyla; PRO-132365; R3502; RG 3502; RG3502-10; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugate

Latest Information Update: 29 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; ImmunoGen
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University College London
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 positive breast cancer
  • Phase II/III Gastric cancer
  • Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Salivary gland cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 19 Jun 2024 Roche completes phase-III clinical trials in HER2-positive-breast-cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA, United Kingdom, Turkey, Spain, Slovenia, Portugal, Poland, Russia, South Korea, Philippines, Norway, Italy, Greece, France, Finland, Croatia, Colombia, China, Canada, Brazil, Australia (IV) (NCT04740918)
  • 23 May 2024 Roche completes a phase III trial in Breast cancer (Adjuvant therapy, Combination therapy, Early-stage disease) in US, EU, Asia, Hong- Kong, Israel, Russia, Taiwan, Turkey, UK, Central and South America, Serbia, South Africa and Switzerland (NCT01772472)
  • 09 May 2024 Roche announces intention to submit regulatory filing for Breast cancer (Adjuvant therapy, Combination therapy) in or after 2027 (Roche pipeline, May 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top